SAB Biotherapeutics Inc
SABS
Get informed when a big investor buys or sells
+ FollowMarket Cap$36.51M
Close$
$0.07
97.9% downside
Current Fair Value
97.9% downsideOvervalued by 97.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.51 Million |
|---|---|
| Enterprise Value | $22.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 0.53 |
| Outstanding Shares | 53,558,639 |
Return
| Return on Equity | -0.18% |
|---|---|
| Return on Assets | -0.16% |
| Return on Invested Capital | -50.99% |
Valuation & Multiples
| P/E Ratio | 8.88 |
|---|---|
| PEG | 3.38 |
| Price to Sales | - |
| Price to Book Ratio | 0.9 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.18 |
| Enterprise Value to Net Income | -56 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3354▲ 33.54% |
|---|---|
| Total Calls | 148,200▲ Infinity% |
| Total Puts | 49,700▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 358.29%▲ 17.38% |
|---|---|
| Total Invested | $265.01M▲ 94.98% |
| Investors Holding | 81▲ 33.00% |
ESG Score
No data
About SAB Biotherapeutics Inc
81 employeessab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.